Archive
529 articles, sorted by publication time.
A 2026 R&D pipeline report has pushed spasticity treatment back into industry view; although candidate drugs remain limited, they show that pharmaceutical companies are trying to find more refined answers than existing muscle relaxants and botulinum toxin, balancing efficacy, dosing convenience, and long-term safety.
MEDIPOST’s CARTISTEM has enrolled and treated the first participant in a U.S. Phase 3 trial, moving a knee cartilage repair therapy that has been used in South Korea for many years into more rigorous cross-market clinical testing.
Whether a tube of blood can provide sufficiently reliable molecular clues in cancer care is becoming a key question for the next stage of precision medicine; the launch of Caris Detect shows that the liquid biopsy market is not only pursuing early detection, but also competing for a role in treatment selection and disease monitoring.
Inspired by a tumor-associated bacterial protein, a UIC team designed the peptide aurB to interfere with mitochondrial energy supply in cancer cells; animal experiments showed a more pronounced effect when it was combined with radiation, but a long process of validation remains before human treatment.
Novartis is buying Myricx Bio for up to $1.5 billion, which on the surface is another acquisition amid the ADC boom; at a deeper level, it signals that large pharmaceutical companies are pushing risk and imagination back to the source of academic translation.
A new industry report has brought several pharmaceutical companies’ graft-versus-host disease pipelines back into focus; the real question is not only whether the number of candidate drugs is increasing, but whether a more precise balance can be found between suppressing immune attack and preserving anti-infection and relapse-prevention capacity.
The study is not only testing whether two drugs can improve survival; it is also testing how clinical trials can truly reach the places where evidence is needed most, amid mistrust, delayed care-seeking, and the shadow of conflict.
The deal is not only a financial move by a large pharmaceutical company to strengthen its pipeline. It also shows that rare endocrine diseases are moving from a niche market toward a more competitive, more capital-intensive stage for new drug development.
EPI-321 aims to use a one-time AAV infusion to re-silence the abnormally activated DUX4 signal behind FSHD; early muscle imaging signals offer clues, but safety, durability and functional improvement still require longer follow-up.
An anticancer candidate therapy has crossed the threshold from preclinical work to human research, but public information remains limited; the real test will begin with safety, dosing, and patient selection.
The race in protein design is no longer only about model size, but about who can obtain biological data that is reliable enough and can be validated back in the laboratory; Atlas’s debut highlights how AI drug discovery is moving from an algorithm-driven narrative toward data infrastructure.
An arXiv preprint reports that a 32B-parameter reasoning model built for rare diseases improved diagnostic hit rates in multicenter validation and a physician-assistance trial; but it also reminds people that the next test for medical AI is not whether it can answer, but how it can be used reliably.